Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Study identifier:D1449C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a double-blind, placebo-controlled study

Medical condition

Social Anxiety Disorder

Phase

Phase 3

Healthy volunteers

Study drug

quetiapine

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jun 2006

Primary Completion Date: 01 Dec 2006

Study Completion Date: 01 Dec 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca The Netherlands

31 (0)79 363 22 22

Investigators

Principal Investigator

AstraZeneca Netherlands Medical Director

AstraZeneca